

**To:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**Cc:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl); 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**From:** 5.1.2e [REDACTED]  
**Sent:** Sun 3/21/2021 5:23:41 PM  
**Subject:** RE: Kind reminder: Updated ECDC long-term surveillance framework  
**Received:** Sun 3/21/2021 5:23:42 PM

Heel erg bedankt [REDACTED] goed punt over delen WGS gerelateerde data. Ik zag verder ook geen bezwaarlijke zaken, en al de reactie zo doorsturen.

Groeten,

[REDACTED]

**From:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**Sent:** Friday, March 19, 2021 10:09 AM  
**To:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**Cc:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl); 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**Subject:** RE: Kind reminder: Updated ECDC long-term surveillance framework

Ho [REDACTED]

Ik heb de punten over SARI surveillance gecheckt bij [REDACTED] (akkoord – landelijke planning in lijn met die van ecdc) en de punten over lab-surveillance tbv multi-country outbreaks bij [REDACTED]. [REDACTED] gaf aan dat het op zich goede objectives zijn en dat hij voor een rol van ECDC is in het detecteren en coördineren van cross-country outbreaks. Dat is waar ze al naar toe bewegen voor FWD. Enige punt is nog wel dat het niet automatisch zo is dat alle wgs en metadata zomaar naar ECDC doorgezet kunnen worden. Op RIVM zijn we ook nog bezig of daar bv geen toestemming voor moeten hebben van de MMLs. Daar zullen meer landen mee worstelen. Het mandaat / tor moet dan ook goed afgesproken worden (wat kan/mag ECDC met deze data en wat niet). De overige punten waren redelijk vanzelfsprekend en lijken me ok. Zie hieronder mijn reactie (lijkt me beter als deze uit jouw mailbox komt?).

Groeten [REDACTED]

Dear ECDC,

Thank you for this extensive framework; it looks very promising and we are enthusiastic about its contents. In general we agree with the vision, objectives, actions and milestones of the ECDC long-term surveillance framework. We were asked to specifically focus on actions 1.1, 1.2, 2.3, 2.4, 2.5, 3.2, 4.2. We agree with all the proposed actions. Regarding action 2.4 (weekly or, where required, real-time laboratory surveillance of suitable outbreak-prone diseases building on existing digital information systems), we do have a point of concern. Although we agree with objective, we foresee that the collection of WGS and its metadata by the ECDC is not straightforward. For the Netherlands, for example, we might require additional permission of the local medical microbiology laboratories for sending sequences to the ECDC. It would then help if the mandate/terms of reference for this data collection by the ECDC is very well defined. We would add this definition as an additional milestone towards the general target. On all the other items we don't have additional comments. We wish you all the best in implementing this framework.

[REDACTED]

RIVM - Centrum Infectieziektenbestrijding CIB  
Epidemiologie en Surveillance, EPI  
Signalering en Surveillance, SIS  
Postbus 1  
3720 BA Bilthoven  
tel [REDACTED] 5.1.2e [REDACTED]

5.1.2e [REDACTED]

---

**From:** 5.1.2e [REDACTED] 5.1.2e (@rivm.nl)  
**Sent:** vrijdag 12 maart 2021 14:57

To: 5.1.2e < 5.1.2e @rivm.nl>

Cc: 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @rivm.nl>

**Subject:** FW: Kind reminder: Updated ECDC long-term surveillance framework

Ho 5.1.2e

Zou jij als (alternate) NFP voor surveillance input op de laatste revisie van dit framework, en dan vooral de specifieke vragen, kunnen coördineren vanuit EPI? Het is bij mij blijven liggen, excusus, deadline is 22 maart.  
Groeten.

5.1.2e

**From:** 5.1.2e

**Sent:** vrijdag 16 oktober 2020 13:37

To: 5.1.2e @ecdc.europa.eu < 5.1.2e @ecdc.europa.eu>

Cc: 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @ecdc.europa.eu>; 5.1.2e @ecdc.europa.eu'

< 5.1.2e @ecdc.europa.eu>; 'PHF Support' < 5.1.2e @ecdc.europa.eu>; 5.1.2e @rivm.nl>

< 5.1.2e @rivm.nl>; 5.1.2e < 5.1.2e @rivm.nl>

**Subject:** ECDC EU surveillance framework 2021-2027 - suggestions

Dear 5.1.2e

Nice to see you and others of the surveillance section last Thursday and thank you for presenting the surveillance framework 2021-2027. Please find comments below:

- Good to see a concise strategy, with important priorities and challenges mentioned, e.g. the surveillance of severe infections in hospitals (which we struggle with in the Netherlands).
- General: I think the COVID-19 crisis raises so many issues at all dimensions of surveillance (data-sources, methods, stakeholders, output, EU added value, etc) that it would be good to plan a dedicated piece of work as part of this strategy to learn as much as possible from the crisis from a surveillance and early warning point of view.
- Objective 2 (unlock data-sources)
  - Big data is now included in the holistic approach. This suggests it is as concrete and well defined as e.g. the molecular surveillance – which it is not really. Its use is also wider than just threat detection and assessment. I think it deserves a separate action, learning e.g. from COVID-19 in which I think two key big data sources are about mobility and about temperature/humidity.
- What I missed was:
  - Training is now mentioned briefly under Action 4.1 (Tailored support), I think it deserves an action in itself ('surveillance workforce development'): the workforce for surveillance needs to be trained in data science methods, including 'data hunting', legal aspects, governance, visualisation and thinking in data products, and we need to hire experts in these areas. This raises questions of role descriptions, which ECDC could help in defining: what is part of the epidemiologists job, what of data managers, lawyers and data scientists. In my current role in COVID surveillance I often think I might function better if I was a lawyer than an epidemiologist.
  - Syndromic surveillance based on citizen science and also (excess) mortality: we should work to make these routine EU surveillance programmes.
  - More general attention to surveillance of determinants of infectious diseases: contact patterns, mobility, temperature/humidity, vaccination coverage, etc.

Detail: for some targets (e.g. evidence published in peer review journals) the target year is stated as 2027. It would be better to say 2021-2027.

To be honest I really missed coming to Stockholm and connecting to the network – but at the same time several yearly meetings at ECDC are not ethical from an environmental/climate (and also time efficiency) point of view. I

think it would be good to gather your and the network's experience about this meeting to inform how best to design a hybrid model of meetings.

With best wishes,

### 5.1.2e

**From:** 5.1.5 ; 5.1.2e ; @ecdc.europa.eu  
**Sent:** Wednesday, March 10, 2021 10:18 AM  
**To:** 5.1.2e <5.1.2e @ordensklinikum.at>; 5.1.2e <5.1.2e @vzbb.sk>; 5.1.2e <5.1.2e @fhi.no>; 5.1.2e <5.1.2e @landlaeknir.is>; 5.1.2e <5.1.2e @njjz.si>; 5.1.2e <5.1.2e @hpse.ie>; 5.1.2e <5.1.2e @insa.min-saude.pt>; 5.1.2e <5.1.2e @insp.gov.ro>; 5.1.2e <5.1.2e @pzh.gov.pl>; 5.1.2e <5.1.2e @med.uea.gr>; 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @nnk.gov.hu>; 5.1.2e <5.1.2e @lzcg.me>  
5.1.2e <5.1.2e @nkk.gov.hu>; 5.1.2e <5.1.2e @arsnorte.min-saude.pt>; 5.1.2e <5.1.2e @inmi.it>; 5.1.2e <5.1.2e @njjz.si>; 5.1.2e <5.1.2e @terviseamet.ee>; 5.1.2e <5.1.2e @folkhalsomyndigheten.se>; 5.1.2e <5.1.2e @rki.de>; 5.1.2e <5.1.2e @gov.mt>; 5.1.2e <5.1.2e @rki.de>; 5.1.2e <5.1.2e @gov.mt>; 5.1.2e <5.1.2e @chl.lu>; 5.1.2e <5.1.2e @gov.mt>; 5.1.2e <5.1.2e @ssi.dk>; 5.1.2e <5.1.2e @gov.mt>; 5.1.2e <5.1.2e @szu.cz>; 5.1.2e <5.1.2e @spkc.gov.lv>; 5.1.2e <5.1.2e @tcd.ie>; 5.1.2e <5.1.2e @msssi.es>; 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @sciensano.be>; 5.1.2e <5.1.2e @who.int>; 5.1.2e <5.1.2e @yahoo.com>; 5.1.2e <5.1.2e @ages.at>; 5.1.2e <5.1.2e @santerepubliquefrance.fr>; 5.1.2e <5.1.2e @szu.cz>; 5.1.2e <5.1.2e @mphs.moh.gov.cy>; 5.1.2e <5.1.2e @ifmed.uniba.sk>; 5.1.2e <5.1.2e @sam.lt>; 5.1.2e <5.1.2e @bkus.lv>; 5.1.2e <5.1.2e @sam.lt>; 5.1.2e <5.1.2e @isciii.es>; 5.1.2e <5.1.2e @sciensano.be>; 5.1.2e <5.1.2e @riva.nl>; 5.1.2e <5.1.2e @ssi.dk>; 5.1.2e <5.1.2e @ec.europa.eu>; 5.1.2e <5.1.2e @ecdc.europa.eu>; 5.1.2e <5.1.2e @ecdc.europa.eu>  
**Cc:** 5.1.2e <5.1.2e @agnihas.lv>; 5.1.2e <5.1.2e @thl.fi>; 5.1.2e <5.1.2e @hse.ie>; 5.1.2e <5.1.2e @mehs.moh.gov.cy>; 5.1.2e <5.1.2e @ifmed.uniba.sk>; 5.1.2e <5.1.2e @sam.lt>; 5.1.2e <5.1.2e @bkus.lv>; 5.1.2e <5.1.2e @sam.lt>; 5.1.2e <5.1.2e @isciii.es>; 5.1.2e <5.1.2e @sciensano.be>; 5.1.2e <5.1.2e @riva.nl>; 5.1.2e <5.1.2e @ssi.dk>; 5.1.2e <5.1.2e @ec.europa.eu>; 5.1.2e <5.1.2e @ecdc.europa.eu>; 5.1.2e <5.1.2e @ecdc.europa.eu>

Dear members of the Advisory Forum,

This is a kind reminder regarding the updated version of the ECDC long-term surveillance framework, for which we are seeking your feedback.

As mentioned, this is an updated version of the document that was discussed during AF63 in December, and we would appreciate your response to the questions included in the cover page.

Please note the deadline for responses is **Monday, 22 March 2021**.

Best regards,

## Executive Office/Governance



**From:** [REDACTED] 5.1.5  
**Sent:** 22 February 2021 14:52  
**To:** [REDACTED] 5.1.2e <[REDACTED]@ordensklinikum.at>; [REDACTED] 5.1.2e <[REDACTED]@vzbb.sk>; [REDACTED] 5.1.2e <[REDACTED]@fhi.no>; [REDACTED] 5.1.2e <[REDACTED]@landlaeknir.is>; [REDACTED] 5.1.2e <[REDACTED]@nijz.si>; [REDACTED] 5.1.2e <[REDACTED]@hpsc.ie>; [REDACTED] 5.1.2e <[REDACTED]@insa.min-saude.pt>; [REDACTED] 5.1.2e <[REDACTED]@pzh.gov.pl>; [REDACTED] 5.1.2e <[REDACTED]@med.uoa.gr>; Dessel Jaap' <[REDACTED]@rivm.nl>; 'van [REDACTED] 5.1.2e <[REDACTED]@nnk.gov.hu>; Dissel Jaap' <[REDACTED]@ijzcg.me>  
**Cc:** [REDACTED] 5.1.2e <[REDACTED]@nnk.gov.hu>; [REDACTED] 5.1.2e <[REDACTED]@thl.fi>; [REDACTED] 5.1.2e <[REDACTED]@hse.ie>; [REDACTED] 5.1.2e <[REDACTED]@mphs.moh.gov.cy>; [REDACTED] 5.1.2e <[REDACTED]@ifmed.uniba.sk>; [REDACTED] 5.1.2e <[REDACTED]@terviseamet.ee>; [REDACTED] 5.1.2e <[REDACTED]@folkhalsomyndigheten.se>; [REDACTED] 5.1.2e <[REDACTED]@gov.mt>; [REDACTED] 5.1.2e <[REDACTED]@ecdc.europa.eu>; [REDACTED] 5.1.2e <[REDACTED]@ecdc.europa.eu>; [REDACTED] 5.1.2e <[REDACTED]@ecdc.europa.eu>; [REDACTED] 5.1.2e <[REDACTED]@sam.lt>; [REDACTED] 5.1.2e <[REDACTED]@chl.lu>; [REDACTED] 5.1.2e <[REDACTED]@gov.mt>; [REDACTED] 5.1.2e <[REDACTED]@rki.de>; [REDACTED] 5.1.2e <[REDACTED]@hzj.hr>; [REDACTED] 5.1.2e <[REDACTED]@tcd.ie>; [REDACTED] 5.1.2e <[REDACTED]@thl.fi>; [REDACTED] 5.1.2e <[REDACTED]@folkhalsomyndigheten.se>; [REDACTED] 5.1.2e <[REDACTED]@sciensano.be>; [REDACTED] 5.1.2e <[REDACTED]@who.int>; [REDACTED] 5.1.2e <[REDACTED]@mssi.es>; [REDACTED] 5.1.2e <[REDACTED]@riva.mnl>; [REDACTED] 5.1.2e <[REDACTED]@ages.at>; [REDACTED] 5.1.2e <[REDACTED]@santepubliquefrance.fr>; [REDACTED] 5.1.2e <[REDACTED]@nijz.si>; [REDACTED] 5.1.2e <[REDACTED]@bkus.lv>; [REDACTED] 5.1.2e <[REDACTED]@sam.lt>; [REDACTED] 5.1.2e <[REDACTED]@iscili.es>; [REDACTED] 5.1.2e <[REDACTED]@rki.de>; [REDACTED] 5.1.2e <[REDACTED]@riva.mnl>; [REDACTED] 5.1.2e <[REDACTED]@sciensano.be>; [REDACTED] 5.1.2e <[REDACTED]@ssi.dk>; [REDACTED] 5.1.2e <[REDACTED]@ssi.dk>  
**Subject:** FOR YOUR REVIEW: Updated ECDC long-term surveillance framework

Dear Advisory Forum colleagues,

Please find attached an updated version of the ECDC long-term surveillance framework.

This is an updated version of the document that was discussed in AF63, and we are now seeking your response to the questions that are included in the cover page. This version includes some clarifications in the text (highlighted in yellow) based on the comments received during AF63 related to the interplay between EU/EEA and national surveillance (section 1) and the concerns of less well-resourced Member States (section 2.5).

Please note the deadline proposed for responses is **Monday, 22 March 2021**.

Kind regards,  
 Executive Office/Governance

#### Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.